Notice2023-28474
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 27, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 247 (Wednesday, December 27, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 247 (Wednesday, December 27, 2023)]
[Notices]
[Pages 89462-89463]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-28474]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Brian Bailey at 301-201-9217, 240-669-
5128, or <a href="/cdn-cgi/l/email-protection#660404070f0a031f260b070f0a48080f0e48010910"><span class="__cf_email__" data-cfemail="bcdededdd5d0d9c5fcd1ddd5d092d2d5d492dbd3ca">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows: Immortalized
Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV
Antibody Discovery.
Description of Technology
Scientists at NIAID have developed two immortalized stable B cell
lines from rhesus macaques that can have value as research tools for
the discovery of neutralizing antibodies of simian origin against HIV
and that may have value in the development of an HIV vaccine. These B
cell lines encode human Bcl-6 and Bcl-xL proteins, which are major
regulators of apoptosis. These B cell lines are derived from the lymph
node of a rhesus macaque (RM) that was infected with SHIV.CH505. It was
discovered that, unlike in humans, rhesus macaque B cells from lymph
nodes are more effectively immortalized than B cells from Peripheral
Blood Mononuclear Cells (PBMCs).
After sample collection and cryopreservation, pro B cells were
isolated, sorted by flow cytometry for populations of interest, then
activated with CD40 ligand and RM IL-2 followed by transduction with a
retroviral vector encoding Bcl-6, Bcl-xL, and green fluorescent protein
(GFL), thereby creating immortalized clonal lines. Two clones were down
selected for their in vitro neutralizing ability against HIV
pseudovirus CH505.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Bcl-6 and Bc-xL immortalization is a valuable and flexible
tool for HIV antibody discovery in rhesus macaques.
<bullet> Contributes to pre-clinical therapeutic and vaccine
development.
Competitive Advantages
<bullet> The cell lines have been characterized and are readily
expandable for bulk applications as well as for making high-throughput
clonal cultures with or without antigen probes in 384-well plates.
Development Stage
<bullet> Research Materials
Inventors: Jakob Samsel, Ph.D.; Richard Koup, MD; Kristin Boswell,
Ph.D.; all of NIAID.
Publications: Samsel, Jakob, et al. ``Rhesus macaque bcl-6/bcl-XL B
cell immortalization: Discovery of HIV-1 neutralizing antibodies from
lymph node.'' Journal of Immunological Methods, vol. 516, May 2023, p.
113445, <a href="https://doi.org/10.1016/j.jim.2023.113445">https://doi.org/10.1016/j.jim.2023.113445</a>.
Intellectual Property: HHS Reference No. E-196-2023-0-EIR-00.
Licensing Contact: To license this technology, please contact Brian
Bailey at 301-201-9217, 240-669-5128, or <a href="/cdn-cgi/l/email-protection#c4a6a6a5ada8a1bd84a9a5ada8eaaaadaceaa3abb2"><span class="__cf_email__" data-cfemail="3f5d5d5e56535a467f525e56531151565711585049">[email protected]</span></a>., and
reference E-196-2023.
[[Page 89463]]
Dated: December 20, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-28474 Filed 12-26-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 27, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.